- Home
- ATAI vs RCS Comparison
ATAI vs RCS Comparison
Compare ATAI & RCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAI
- RCS
- Stock Information
- Founded
- ATAI 2018
- RCS 1994
- Country
- ATAI Germany
- RCS United States
- Employees
- ATAI N/A
- RCS N/A
- Industry
- ATAI Biotechnology: Pharmaceutical Preparations
- RCS Investment Managers
- Sector
- ATAI Health Care
- RCS Finance
- Exchange
- ATAI Nasdaq
- RCS Nasdaq
- Market Cap
- ATAI 282.6M
- RCS 296.3M
- IPO Year
- ATAI 2021
- RCS N/A
- Fundamental
- Price
- ATAI $2.49
- RCS $6.56
- Analyst Decision
- ATAI Strong Buy
- RCS
- Analyst Count
- ATAI 3
- RCS 0
- Target Price
- ATAI $10.50
- RCS N/A
- AVG Volume (30 Days)
- ATAI 2.4M
- RCS 141.1K
- Earning Date
- ATAI 05-14-2025
- RCS 01-01-0001
- Dividend Yield
- ATAI N/A
- RCS 10.12%
- EPS Growth
- ATAI N/A
- RCS N/A
- EPS
- ATAI N/A
- RCS N/A
- Revenue
- ATAI $1,863,000.00
- RCS N/A
- Revenue This Year
- ATAI $242.21
- RCS N/A
- Revenue Next Year
- ATAI N/A
- RCS N/A
- P/E Ratio
- ATAI N/A
- RCS N/A
- Revenue Growth
- ATAI 572.56
- RCS N/A
- 52 Week Low
- ATAI $1.03
- RCS $4.51
- 52 Week High
- ATAI $2.64
- RCS $6.31
- Technical
- Relative Strength Index (RSI)
- ATAI 80.34
- RCS 73.99
- Support Level
- ATAI $2.18
- RCS $6.29
- Resistance Level
- ATAI $2.38
- RCS $6.35
- Average True Range (ATR)
- ATAI 0.20
- RCS 0.11
- MACD
- ATAI 0.07
- RCS 0.02
- Stochastic Oscillator
- ATAI 88.14
- RCS 98.80
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
About RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.